Friday 6 November 2026 Export IONS’s income statement to Excel — free account

Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $943.7 million, up 33.8% from fiscal 2024.

Revenue: −40.7%
EPS: −188.5%
Free cash flow: +299.3%
Total debt: +116.0%

Quarter to June 2026, against a year earlier

Insider buying

39.48 0.68 +1.75%

Follow IONS

Alert me

Market cap: $6.5B
P/E: 0.0×
Fwd P/E: −12.2×
Dividend yield: —
F-score: 4/9
Altman Z: 2.12
Beneish M: −3.13
Dividend safety: n/a

Overview Business Profile Segments Valuation Filings

Ionis Pharmaceuticals, Inc. (IONS) P/S ratio

Alert me on P/S ratio

As of 6 November 2026, Ionis Pharmaceuticals, Inc. (IONS) trades at a P/S ratio of 7.5×. Over the past ten years it has ranged from 5.2× (March 2020) to 42.4× (March 2015); the current reading is higher than 22% of that period. That is below the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/IONS/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Ionis Pharmaceuticals, Inc. P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/IONS/metrics/ps-ratio">Ionis Pharmaceuticals, Inc. (IONS) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2025	13.4×	80.95%
FY2024	7.4×	(22.88%)
FY2023	9.6×	5.91%
FY2022	9.1×	71.40%
FY2021	5.3×	(51.08%)
FY2020	10.8×	43.68%
FY2019	7.5×	(36.84%)
FY2018	11.9×	0.42%
FY2017	11.9×	(22.65%)
FY2016	15.4×	(41.23%)

Period	P/S ratio	Change
Jun 2026	15.0×	28.26%
Mar 2026	11.7×	(12.78%)
Dec 2025	13.4×	24.09%
Sep 2025	10.8×	62.29%
42 more quarters	Free account

Against its own ten years

Low 5.2× High 42.4×

Ten-year median 10.4×

Current reading's percentile 22

Company	P/S ratio
BLTE Belite Bio, Inc. Sponsored ADR compare	n/m
IMVT Immunovant, Inc. compare	n/m
ORKA Oruka Therapeutics, Inc. compare	n/m
KOD Kodiak Sciences Inc. compare	n/m
IONS Ionis Pharmaceuticals, Inc.	7.4×
AXSM Axsome Therapeutics, Inc. compare	7.8×
MIRM Mirum Pharmaceuticals, Inc. compare	9.2×
LGND Ligand Pharmaceuticals Incorporated compare	23.6×
CGON CG Oncology, Inc. compare	919×
Biotechnology industry median	9.2×
Healthcare sector median	3.5×
Market median	1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

Ionis Pharmaceuticals, Inc. (IONS) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on IONS

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on IONS

Stockrow Weekly